Horizon Pharma, Inc.
HZNP announced today the pricing of an underwritten public
offering of 21,425,000 units, with each unit consisting of one share
of its common stock and a warrant to purchase 0.5 of a share of its
common stock. The shares of common stock and warrants are being
offered at a combined price to the public of $3.50 per unit. The
gross proceeds to Horizon from this offering are expected to be
approximately $75 million, before deducting underwriting discounts
and other offering expenses payable by Horizon. The warrants will be
exercisable at $4.57 per share and will expire five years from the
date of issuance. The shares of common stock and warrants are
immediately separable and will be issued separately. Horizon has
granted the underwriters a 30-day option to purchase up to an
aggregate of 3,213,750 additional shares of common stock and warrants
to purchase 1,606,875 shares of common stock to cover overallotments,
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in